Business
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Issues Update on Intellectual Property and Newly Acquired Patents
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Issues Update on Intellectual Property and Newly Acquired Patents.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Issues Update on Intellectual Property and Newly Acquired Patents\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Issues Update on Intellectual Property and Newly Acquired Patents\nPR Newswire\nSAN DIEGO, Jan. 23, 2020\n\n\n\nSAN DIEGO, Jan. 23, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its portfolio investment company Kannalife, Inc. (\"Kannalife\") (OTC: KLFE) recently provided an update on its intellectual property revolving around its global WIPO/PCT Patent WO2015/106108A2 titled \"Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy\" (the \"PCT Patent\").\n\"We are proud to have Kannalife as part of our investment portfolio as they are continuously reaching new milestones in researching cannabinoid therapeutics,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"The amount of research in this space has increased tremendously over the past year but there is still significant progress to be made. It's encouraging to see Kannalife at the forefront of this.\"\nSince the filing of the PCT Patent in 2015, Kannalife has received patent approval in the following jurisdictions: U.S. Patent 9,611,213 \"Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,\" U.S. Patent 10,004,722 \"Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols,\" Japanese Patent JP6486950B2 \"Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy\" and Russian Patent RU2676475C2 \"Novel Functionalized 1,3-Benzene Diols and their Method of U...